$RTX

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq Composite and Russell 2000 led a three-day market rally, with Nasdaq up 2.14% and Russell 2000 up 2.36% for the week. The Dow and S&P 500 also gained over 1.2%. Several companies reported earnings, including RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group (Nasdaq: CME), M/I Homes (NYSE: MHO), and Lockheed Martin (NYSE: LMT). RTX reported $25.0B in Q3 sales and raised its full-year outlook. Abbott posted 14.5% sales growth. CME Group saw record Q3 revenue.

Original reporting
Published Oct 21, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm — source image
Decision brief

The 30-second read

$RTXBullishHigh
01

Why it matters

Earnings beats and guidance upgrades drive sector‑specific momentum, while weaker homebuilder data dampens that theme.

02

Market read

Broad market gains are underpinned by strong earnings from large caps; small‑cap rally adds breadth.

03

What to watch

Potential supply‑chain constraints for homebuilders and defense procurement budget caps could temper optimism.

Relevance 8/10Novelty 8/10Timing: same-day today

Background

Market wrap highlighting Nasdaq and small‑cap rally, with detailed Q3 earnings for five listed companies.

Company-level read

Ticker impact

$RTXBullishHigh confidence
Context

RTX reported Q3 sales up 11% and raised full‑year 2026 outlook to $97‑$97.5 B revenue and $7.65‑$7.75 EPS.

Expected impact

likely upward pressure as investors price in higher sales and earnings outlook

Evidence & confidence

Guidance increase of ~2% revenue and ~7% EPS is material for a large aerospace/defense firm.

$ABTNeutralMedium confidence
Context

Abbott posted Q3 sales growth of 14.5% and reaffirmed FY 2026 EPS guidance at $5.50‑$5.55.

Expected impact

moderate upside as market digests solid growth and stable guidance

Evidence & confidence

Earnings beat and guidance hold, but no surprise lift.

$CMEBullishHigh confidence
Context

CME Group posted Q3 revenue $1.7 B, net income $1.0 B and returned nearly $1 B to shareholders.

Expected impact

upward pressure from dividend and buyback plus strong earnings

Evidence & confidence

Double‑digit earnings growth and shareholder returns are material for a market‑data leader.

$MHOBearishMedium confidence
Context

M/I Homes reported Q3 revenue down 5% and earnings decline, but repurchased $50 M of stock.

Expected impact

downward pressure as revenue and earnings miss expectations

Evidence & confidence

Revenue decline and lower net income signal demand weakness in homebuilding.

$LMTBullishLow confidence
Context

Lockheed Martin delivered a C‑130J‑30 aircraft to the U.S. Navy, marking the start of a conversion program.

Expected impact

slight upside as the delivery underscores pipeline strength

Evidence & confidence

Delivery is a routine program milestone without new financial impact.

Market effects

Strong earnings in aerospace, healthcare, and market‑data sectors support sector‑wide bullish bias.

U.S. equities gain broadly; small‑cap Russell 2000 also up, indicating broad market strength.

Positive U.S. earnings feed global risk appetite, reinforcing bullish sentiment in overseas markets.

Counterpoint

If guidance lifts are modest, investors may already price them in, limiting upside.

Key entities

  • Raytheon Technologies

    RTX

  • Abbott Laboratories

    ABT

  • CME Group

    CME

  • M/I Homes

    MHO

  • Lockheed Martin

    LMT

Related articles

$ABTHighAI 8/10

Abbott options flow points to downside caution after guidance cut

Abbott Laboratories (ABT) shares fell 3.56% to $98.80 after Q3 results met EPS estimates and slightly beat revenue forecasts, but full-year sales growth guidance was lowered to 6%. Options flow showed a defensive tilt with 58% puts, including a diagonal put spread of 2,224 contracts. Implied volatility and downside put costs decreased, suggesting the market has priced in the earnings reset.

$CMEHighAI 9/10

CME (CME) Q3 2026 Earnings Call Transcript

CME Group reported Q3 2026 revenue of $1.7B, up 13% YoY, with record market data revenue of $243M. International volume reached 9M contracts/day, up 22% YoY. New products were launched, and cloud migration progress was shared. Adjusted EPS was $3.02, up 13% YoY. The company returned $1B to shareholders. Compute Futures progress depends on CFTC approval.

$RTXHighAI 8/10

RTX Corporation (RTX) Strong Earnings and Cash Flow Make It an Aerospace Dividend Favorite

RTX Corporation (RTX) reported strong Q2 earnings, with Pratt & Whitney and Collins Aerospace segments driving growth. The company raised its 2026 sales and EPS guidance. Despite a 37% pullback from highs, RTX trades at a premium with a P/E of 33x. Free cash flow improved to $2.88B in Q2, supporting dividends. Institutional positioning remains strong, with Fisher Asset Management and Point72 increasing stakes.

$ABTHighAI 8/10

Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition

Abbott Laboratories (ABT) reported Q3 adjusted EPS of $1.42, with revenue up 14.5% YoY to $13.01B. Q4 EPS guidance met expectations, but full-year 2026 sales growth forecast was lowered to ~6%. The company plans to spin off its Nutrition business by the end of 2027, aiming to focus on higher-growth healthcare sectors. Medical Devices and Diagnostics saw strong growth, while Diabetes Care faced reimbursement challenges.

$ABTMedAI 8/10

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call

Abbott Laboratories (ABT) reported Q3 comparable sales up 7% and adjusted EPS of $1.42, in line with guidance. The company expects sales growth to accelerate post-nutrition separation and forecasts Q4 adjusted EPS of $1.62-$1.67. Abbott also provided updates on its medical device pipeline and near-term pressures in electrophysiology and diabetes care.